Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment

Gut

Volumn 65, Issue 5, 2016, Pages 721-725

  Rugge, Massimo ^a,b   Genta, Robert M ^c,d   Graham, David Y ^e   Di Mario, Francesco ^f   Vaz Coelho, Luiz Gonzaga ^g   Kim, Nayoung ^h   Malfertheiner, Peter ⁱ   Sugano, Kentaro ^j   Tsukanov, Vladislav ^k   Correa, Pelayo ^l  

^a UNIVERSITY OF PADOVA   (Italy)

^b Tumor Registry of the Veneto Region   (Italy)

^c MIRACA LIFE SCIENCES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PARMA   (Italy)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ OTTO VON GUERICKE UNIVERSITY   (Germany)

^j JICHI MEDICAL UNIVERSITY   (Japan)

^k INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEPSINOGEN I; PEPSINOGEN II;

ADVANCED CANCER; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL PRACTICE; DISEASE ASSOCIATION; ESOPHAGOGASTRODUODENOSCOPY; GASTRITIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; TREATMENT INDICATION; PATHOLOGY; STOMACH NEOPLASMS; TIME FACTOR;

HUMANS; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84960877985     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310846     Document Type: Article

References (50)

1. Morson BC, Sobin LH, Grundmann E, et al. Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol 1980;33:711-21.
2. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-60.
3. [No authors listed]. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-240.
4. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut 2015;64:1650-68.
5. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
6. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-58.
7. Sena Teixeira Mendes L, D Attygalle A, C Wotherspoon A. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation. Gut 2014;63:1526-7.
8. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61:507-13.
9. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
10. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015;20:25-40.
11. Saka A, Yagi K, Nimura S. OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy. Dig Endosc 2015;27:734-41.
12. Kaise M, Kato M, Tajiri H. High-definition endoscopy and magnifying endoscopy combined with narrow band imaging in gastric cancer. Gastroenterol Clin North Am 2010;39:771-84.
13. Okubo M, Tahara T, Shibata T, et al. Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis. Digestion 2011;83:161-6.
14. Lee JY, Kim N, Lee HS, et al. Correlations among endoscopic, histologic and serologic diagnoses for the assessment of atrophic gastritis. J Cancer Prev 2014;19:47-55.
15. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, et al. Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol 2012;24:37-41.
16. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
17. Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology 2005;129:1807-8.
18. Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging & gastric cancer risk: a twelve year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31:1104-11.
19. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8.
20. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th edn. New York: Wiley-Liss, 2002.
21. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011;17:4596-601.
22. Isajevs S, Liepniece-Karele I, Janciauskas D, et al. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch 2014;464:403-7.
23. Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer 2015;136:425-34.
24. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981;13:931-9.
25. Cassaro M, Rugge M, Gutierrez O, et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95:1431-8.
26. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002;16:1249-59.
27. Jass JR, Walsh MD. Altered mucin expression in the gastrointestinal tract: a review. J Cell Mol Med 2001;5:327-51.
28. Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010;138:2207-10.
29. Sousa JF, Nam KT, Petersen CP, et al. miR-30-HNF4gamma and miR-194-NR2F2 regulatory networks contribute to the upregulation of metaplasia markers in the stomach. Gut Published Online First: 23 Mar. 2015. doi:10.1136/gutjnl-2014-308759
30. Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 1973;18:426-40.
31. Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis-pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10:529-41.
32. Zhang Y, Weck MN, Schöttker B, et al. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev 2013;22:821-6.
33. Genta RM, Rugge M. Atrophic gastritis in the arctic. Clin Gastroenterol Hepatol 2015;13:1601-3.
34. Rugge M, Fassan M, Pizzi M, et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther 2012;35:1460-6.
35. Murphy G, Dawsey SM, Engels EA, et al. Cancer risk after pernicious anemia in the US elderly population. Clin Gastroenterol Hepatol 2015;13:2282-9.e4.
36. Kuipers EJ. Pernicious anemia, atrophic gastritis, and the risk of cancer. Clin Gastroenterol Hepatol 2015;13:2290-2.
37. Weis VG, Sousa JF, LaFleur BJ, etal. Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression. Gut 2013;62:1270-9.
38. Carmack SW, Genta RM, Schuler CM, etal. The current spectrum of gastric polyps: a 1-year national study of over 120, 000 patients. Am J Gastroenterol 2009;104:1524-32.
39. Shaib YH, Rugge M, Graham DY, etal. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol 2013;11:1374-84.
40. Park do Y, Lauwers GY. Gastric polyps: classification and management. Arch Pathol Lab Med 2008;132:633-40.
41. Aiko T, Sasako M. The new Japanese classification of gastric carcinoma: points to be revised. Gastric Cancer 1998;1:25-30.
42. Rugge M, Farinati F, Di Mario F, etal. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 1991;22:1002-8.
43. Rugge M, Cassaro M, Di MF, etal. The long term outcome of gastric non-invasive neoplasia. Gut 2003;52:1111-16.
44. Rugge M, Correa P, Dixon MF, etal. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167-76.
45. Lauwers GY, Carneiro F, Graham DY, et al. WHO Classification of Tumors of the Digestive System. Tumours of the stomach: gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, et al, eds. 4th edn. Lyon: IARC, 2010:48-58.
46. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
47. Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013;27:205-23.
48. van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015;52:361-74.
49. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
50. Rugge M. Secondary prevention of gastric cancer. Gut 2007;56:1646-7.